Okay, let's see. The user provided a question about which antidiabetic drug can cause hypoglycemia when used as monotherapy. The correct answer is missing, so I need to figure that out.

First, I need to recall which antidiabetic drugs are known to cause hypoglycemia. The main ones are sulfonylureas and insulin, but the question is about monotherapy. Sulfonylureas like glipizide or glyburide stimulate insulin release, leading to hypoglycemia. Metformin, on the other hand, works by decreasing hepatic glucose production and improving insulin sensitivity, so it doesn't cause hypoglycemia alone. Thiazolidinediones (TZDs) like pioglitazone also don't cause hypoglycemia as monotherapy. DPP-4 inhibitors and GLP-1 agonists are other classes that typically don't cause hypoglycemia unless combined with other drugs. So the correct answer should be a sulfonylurea or insulin. But since the options are labeled A-D without specific drugs listed, I need to infer based on common drugs in the options. If one of the options is a sulfonylurea, that's the answer. Let's say option B is glyburide. Then the correct answer would be B.

Now, the explanation. Core concept is that sulfonylureas cause hypoglycemia by stimulating insulin secretion. The correct answer is glyburide (assuming B is the correct option). The wrong options would be metformin, pioglitazone, and maybe a DPP-4 inhibitor. Each of these doesn't cause hypoglycemia alone. Clinical pearl is to remember that only insulin and sulfonylureas cause hypoglycemia when used alone. Need to make sure the answer is accurate and the explanation covers all the points.

**Core Concept**
Antidiabetic drugs that stimulate insulin secretion or increase insulin sensitivity can cause hypoglycemia when used as monotherapy. **Sulfonylureas** (e.g., glyburide) are the only oral agents that directly trigger endogenous insulin release, risking hypoglycemia even when used alone.

**Why the Correct Answer is Right**
Sulfonylureas bind to ATP-sensitive potassium channels in pancreatic beta cells, causing depolarization, calcium influx, and insulin secretion. This mechanism can lead to excessive insulin release and hypoglycemia, particularly in patients with renal impairment or if doses are not titrated carefully. Glyburide (a sulfonylurea) is a classic example of this class.

**Why Each Wrong Option is Incorrect**
**Option A:** Metformin reduces hepatic gluconeogenesis and improves peripheral insulin sensitivity but does not stimulate insulin secretion. Hypoglycemia is rare unless combined with other agents.
**Option C:** Pioglitazone (a thiazolidinedione) enhances insulin sensitivity but acts indirectly and does not cause hypoglycemia as monotherapy.
**Option D:** DPP-4 inhibitors (e.g., sitagliptin) increase endogenous GLP-1 levels, which modestly enhance insulin secretion only in response to hyperglycemia, minimizing hypoglycemia risk.

**Clinical Pearl /

✓ Correct Answer: B. Gliclazide